What we do

Our oncology centres offer a holistic care model with technologically advanced diagnostic and interventional services supporting comprehensive cancer management.

Our significant investment in technologies place our oncology centres at the forefront of advanced treatments in surgical, medical, gynaelogical and radiation oncology.

Life Healthcare provides specialised healthcare facilities that offer both inpatient and outpatient services, including acute rehabilitation, mental healthcare, renal dialysis and oncology. Our specialised care model promotes continuity of care and uniquely positions Life Healthcare to provide comprehensive therapeutic interventions for chronically ill patients.

Facilities that provide for patients with disabling or traumatic brain injuries, offering acute physical and cognitive rehabilitation. Our focus on patient care helps to restore quality of life for our patients and their families.

Life Rehabilitation uses the Functional Assessment Measure (FAM) for cognitive, behavioural, communication and community functioning, which provides insight on patients with brain injuries. We measure the clinical outcomes of each patient and track their overall progress to benchmark the performance of rehabilitation units and denote clear patient outcomes. In this way, we can support patients’ families and provide in-depth detail to healthcare funders during the rehabilitation process.

Life Rehabilitation is International Standards Organisation (ISO) 9001 2015 certified and also a certified licence holder for the Functional Independence Measure™ (FIM™) in South Africa, which allows us to evaluate the functional status of patients during their rehabilitation process.

For patients with renal failure who need outpatient-based chronic dialysis, inpatient-based acute renal dialysis or home-based peritoneal dialysis.

Multi-disciplinary mental healthcare service offerings, designed for transitory care in a therapeutic and tranquil environment. Our facilities house voluntary, assisted and involuntary mental healthcare users. We also operate theatres with anaesthetic capability for electroconvulsive therapy.

We offer specialised care for the most vulnerable in our society. We partner with South Africa’s provincial health and social development departments to provide comprehensive, long-term services. These services are offered on contract, which are awarded through the National Treasury tender processes.

We offer an integrated health risk management service providing wellness programmes, occupational and primary healthcare to corporate and institutional clients.

We provide contracted on-site occupational and primary healthcare services to large employer groups in various industries and various government departments, and specialise in implementing and delivering comprehensive health strategies for employees.

We furthermore provide outcomes-based employee wellness programmes (EWPs), helping companies and institutions in the public and private sector to encourage and support healthy and balanced living for their employees. The goal is to improve their well-being and promote maximum productivity through health.

Diagnostic and molecular imaging, radiopharmaceuticals and product development.

As western Europe’s leading independent provider of diagnostic imaging services, we improve patient care by combining innovative imaging technologies and excellent service.

We support public and private organisations with their imaging requirements, and work collaboratively with healthcare professionals, healthcare organisations and academic institutions – ensuring high-quality yet cost-effective care for our patients and customers.

Our principal offerings

UK

• Magnetic resonance imaging (MRI)
• Computerised tomography (CT)
• Positron emission tomography-computerised tomography (PET-CT)
• Radiopharmacy

Our principal offerings

LMI

A fully integrated research and development pharma company dedicated to developing and globally commercialising innovative molecular imaging agents for use in PET-CT diagnostics. LMI has a pipeline of novel imaging agents that address major unmet clinical needs in neurological, oncological and cardiovascular diseases.

Neuraceq^TM (florbetaben F18), is FDA approved with the second largest market share in US.